Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies.
Related Articles Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies.
Sci Rep. 2016;6:32201
Authors: Japelj B, Ilc G, Maruši? J, Sen?ar J, Kuzman D, Plavec J
Abstract
Biosimilar drug products must have a demonstrated similarity with respect to the reference product's molecules in order to ensure both the effectiveness of the drug and the patients' safety. In this paper the fusion framework of a highly sensitive NMR fingerprinting approach for conformational changes and mathematically-based biosimilarity metrics is introduced. The final goal is to translate the complex spectral information into biosimilarity scores, which are then used to estimate the degree of similarity between the biosimilar and the reference product. The proposed method was successfully applied to a small protein, i.e., filgrastim (neutropenia treatment), which is the first biosimilar approved in the United States, and a relatively large protein, i.e., monoclonal antibody rituximab (lymphoma treatment). This innovative approach introduces a new level of sensitivity to structural changes that are induced by, e.g., a small pH shift or other changes in the protein formulation.
PMID: 27578487 [PubMed - in process]
More...